期刊文献+

胆囊癌外科规范化治疗策略的探讨与思考 被引量:2

Surgical treatment of gallbladder cancer: Strategy and optimization
下载PDF
导出
摘要 胆囊癌是胆道系统最常见的恶性肿瘤,因其缺乏早期特异性症状和体征,因此多数病例发现时已属中晚期,且对放化疗不敏感,总的预后较差.根治性的胆囊癌切除术可延长患者的生存时间,然而目前对于具体手术方式的选择尚存在一些争议.本文就胆囊癌术式的合理规范化选择进行分析和探讨,希望提高对于胆囊癌手术治疗的认识. Gallbladder cancer is the most common malignant tumor of the biliary tract. It is difficult to diagnose early due to the lack of special symptoms and physical signs. Most cases are diagnosed in advanced stages and the response to traditional chemotherapy and radiotherapy is extremely limited, with modest impact on overall survival. Despite improvements in outcome associated with extended resections, selection of patients for such extensive surgery remains controversial. In this article, we analyze and discuss the key issues about the surgical management of gallbladder cancer, with the hope of a more comprehensive recognition of this malignancy.
出处 《世界华人消化杂志》 CAS 2015年第12期1865-1872,3,共8页 World Chinese Journal of Digestology
关键词 胆囊癌 外科治疗 R0切除 淋巴清扫 Gallbladder cancer Surgical treatment RO resection Lymphadenectomy
  • 相关文献

参考文献82

  • 1Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014; 6:99-109 [PMID: 24634588 DOI: 10.2147/CLEP. $37357].
  • 2Lazcano-Ponce EC, Miquel JF, Muoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51:349-364 [PMID: 11760569 DOI: 10.3322/ canjclin.51.6.349].
  • 3Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer ] Clin 2015; 65:5-29 [PMID: 25559415 DOI: 10.3322/caac.21254].
  • 4Lam CM, Yuen AW, Wai AC, Leung RM, Lee AY, Ng KK, Fan ST. Gallbladder cancer presenting with acute cholecystitis: a population-based study. Surg Endosc 2005; 19:697-701 [PMID: 15776204 DOI: 10.1007/s00464-004-9116-2].
  • 5Andrn-Sandberg A, Deng Y. Aspects on gallbladder cancer in 2014. Curt Opin Gastroenterol 2014; 30:326-331 [PMID: 24686434 DOI: 10.1097/ MOG.0000000000000068].
  • 6Sheth S, Bedford A, Chopra S. Pr/mary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am l Gastroenterol 2000; 95:1402-1410 [PMID: 10894571 DOI: 10.1111/ /.1572-0241.2000.02070.x].
  • 7Balachandran P, Agarwal S, Krishnani iN, Pandey CM, Kumar A, Sikora SS, Saxena R, Kapoor VK. Predictors of long-term survival in patients with gallbladder cancer. ] Gastrointest Surg 2006; 10:848-854 [PMID: 16769541 DOI: 10.1016/ j.gassur.2005.12.002].
  • 8Wullstein C, Woeste G, Barkhausen S, Gross E, Hopt UT. Do complications related to laparoscopic cholecystectomy influence the prognosis of gallbladder cancer? Surg Endosc 2002; 16:828-832 [PMID: 11997831 DOE 10.1007/s00464-001-9085-7].
  • 9Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg 2008; 196:252-264 [PMID: 18466866 DOI: 10.1016/j.amjsurg.2007.11.011].
  • 10Kiran RP, Pokala N, Dudrick SJ. Incidence pattern and survival for gallbladder cancer over three decades--an analysis of 10301 patients. Ann Surg Oncol 2007; 14:827-832 [PMID: 17109082 DOI: 10.1245/s104,34-006-92244].

同被引文献21

  • 1Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome [ J]. Clini Epidemiol, 2014,6:99 - 109.
  • 2Siegel RL, Miller KD, Jemal A. Cancer statistics ,2015 [ J]. CA Cancer J Clin, 2015,65(1) :5 -29.
  • 3Wang RT, Xu XS, Liu J, et al. prognostic factors in 132 cases[ J]. Gallbladder carcinoma: analysis of Asian Pac J Cancer Prey, 2012,13(6):2511 -2514.
  • 4Russell MR, Levin K, Rader J, et al. Combination therapy targeting the Chkl and Weel kinases shows therapeutic efficacy in neuroblastoma [J]. Cancer Res, 2013,73(2) :776 -784.
  • 5Shigetomi H, Sudo T, Shimada K, et al. Inhibition of cell death and in- duction of G2 arrest accumulation in human ovarian clear cells by HNF - ll3transeription factor: Chemosensitivity is regulated by checkpoint ki- nase CHK1 [J]. Int J Gynecol Cancer, 2014,24(5) :838 - 843.
  • 6Andren - Sandberg A, Deng Y. Aspects on gallbladder cancer in 2014 [ J]. Curr Opin Gastroentero], 2014,30(3) :326 - 31.
  • 7Xiao Y, Ramiscal J, Kowanetz K, et al. Identification of preferred che- motherapeutics for combining ~th a CHK1 inhibitor[ JJ. Mol Cancer T- her, 2013,1201) :2285 -2295.
  • 8Dent P, Tang Y, Yacoub A, et al. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle [ J ]. Mol Interv, 2011,11 (2) :133 - 140.
  • 9Engelke CG, Parsels LA, Qian Y, et al. Sensitization of pancreatic canc- er to chemoradiation by the Chkl inhibitor MK8776 [ J ]. Clin Cancer Res, 2013,19(16) :4412 -4421.
  • 10Kobayashi I-I, Shigetomi I-l, Yoshimoto C. Checkpoint kinase 1 inhibi- tors as targeted molecular agents for clear cell carcinoma of the ovary [J]. 0ncol Lett, 2015,10(2) :571 -576.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部